Free Trial

Tarsus Pharmaceuticals (TARS) Competitors

Tarsus Pharmaceuticals logo
$55.37 -0.26 (-0.47%)
As of 12:40 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

TARS vs. GRFS, RYTM, ABVX, CYTK, LEGN, AXSM, NUVL, RNA, MRUS, and CRSP

Should you be buying Tarsus Pharmaceuticals stock or one of its competitors? The main competitors of Tarsus Pharmaceuticals include Grifols (GRFS), Rhythm Pharmaceuticals (RYTM), Abivax (ABVX), Cytokinetics (CYTK), Legend Biotech (LEGN), Axsome Therapeutics (AXSM), Nuvalent (NUVL), Avidity Biosciences (RNA), Merus (MRUS), and CRISPR Therapeutics (CRSP). These companies are all part of the "pharmaceutical products" industry.

Tarsus Pharmaceuticals vs. Its Competitors

Tarsus Pharmaceuticals (NASDAQ:TARS) and Grifols (NASDAQ:GRFS) are both mid-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, media sentiment, risk, analyst recommendations, profitability, institutional ownership, dividends and earnings.

Grifols has higher revenue and earnings than Tarsus Pharmaceuticals. Tarsus Pharmaceuticals is trading at a lower price-to-earnings ratio than Grifols, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Tarsus Pharmaceuticals$182.95M12.77-$115.55M-$2.33-23.76
Grifols$7.81B0.86$169.80M$1.178.39

Grifols has a net margin of 0.00% compared to Tarsus Pharmaceuticals' net margin of -31.13%. Grifols' return on equity of 0.00% beat Tarsus Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Tarsus Pharmaceuticals-31.13% -32.36% -21.04%
Grifols N/A N/A N/A

In the previous week, Tarsus Pharmaceuticals and Tarsus Pharmaceuticals both had 2 articles in the media. Tarsus Pharmaceuticals' average media sentiment score of 1.78 beat Grifols' score of 1.13 indicating that Tarsus Pharmaceuticals is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Tarsus Pharmaceuticals
2 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive
Grifols
2 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Tarsus Pharmaceuticals currently has a consensus target price of $66.67, suggesting a potential upside of 20.40%. Grifols has a consensus target price of $10.30, suggesting a potential upside of 4.94%. Given Tarsus Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Tarsus Pharmaceuticals is more favorable than Grifols.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Tarsus Pharmaceuticals
0 Sell rating(s)
2 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.71
Grifols
0 Sell rating(s)
3 Hold rating(s)
1 Buy rating(s)
1 Strong Buy rating(s)
2.60

Tarsus Pharmaceuticals has a beta of 0.81, suggesting that its share price is 19% less volatile than the S&P 500. Comparatively, Grifols has a beta of 0.64, suggesting that its share price is 36% less volatile than the S&P 500.

90.0% of Tarsus Pharmaceuticals shares are owned by institutional investors. 9.0% of Tarsus Pharmaceuticals shares are owned by insiders. Comparatively, 0.2% of Grifols shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Tarsus Pharmaceuticals and Grifols tied by winning 8 of the 16 factors compared between the two stocks.

Get Tarsus Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for TARS and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TARS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

TARS vs. The Competition

MetricTarsus PharmaceuticalsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$2.34B$3.12B$5.71B$10.36B
Dividend YieldN/A2.36%5.53%4.58%
P/E Ratio-23.7620.9076.4126.50
Price / Sales12.77255.07469.6091.99
Price / CashN/A46.3537.4661.85
Price / Book9.439.7713.136.40
Net Income-$115.55M-$52.73M$3.29B$271.39M
7 Day Performance7.12%4.37%2.40%2.73%
1 Month Performance-3.29%5.89%4.42%7.23%
1 Year Performance67.63%18.56%73.40%29.46%

Tarsus Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
TARS
Tarsus Pharmaceuticals
2.2291 of 5 stars
$55.37
-0.5%
$66.67
+20.4%
+67.7%$2.34B$182.95M-23.7650
GRFS
Grifols
3.9318 of 5 stars
$9.63
-2.5%
$10.30
+7.0%
+11.9%$6.79B$7.81B8.2323,822
RYTM
Rhythm Pharmaceuticals
3.2599 of 5 stars
$96.03
-0.2%
$101.57
+5.8%
+93.3%$6.39B$156.29M-31.90140Positive News
ABVX
Abivax
2.4446 of 5 stars
$85.87
+2.2%
$99.43
+15.8%
+655.2%$6.35BN/A0.0061Gap Up
CYTK
Cytokinetics
4.232 of 5 stars
$49.44
-3.3%
$75.38
+52.5%
-6.8%$6.12B$18.47M-9.69250Trending News
Analyst Forecast
Analyst Revision
LEGN
Legend Biotech
3.1512 of 5 stars
$33.88
+2.3%
$74.22
+119.1%
-28.3%$6.11B$627.24M-38.502,609Positive News
AXSM
Axsome Therapeutics
4.85 of 5 stars
$116.78
-1.4%
$177.86
+52.3%
+29.1%$5.91B$495.03M-23.03380Insider Trade
NUVL
Nuvalent
3.1209 of 5 stars
$79.37
-1.4%
$120.91
+52.3%
-20.5%$5.80BN/A-16.2040
RNA
Avidity Biosciences
2.0717 of 5 stars
$40.22
-10.1%
$68.94
+71.4%
-2.8%$5.76B$10.90M-11.30190Analyst Forecast
MRUS
Merus
3.1601 of 5 stars
$68.09
-2.1%
$88.75
+30.3%
+42.8%$5.26B$36.13M-12.3837Positive News
CRSP
CRISPR Therapeutics
3.237 of 5 stars
$57.84
+2.8%
$71.60
+23.8%
+30.0%$5.12B$37.31M-10.65460Analyst Forecast

Related Companies and Tools


This page (NASDAQ:TARS) was last updated on 9/24/2025 by MarketBeat.com Staff
From Our Partners